诺和诺德在美上市股价周二暴跌13%，此前这家制药商意外警告称，其2026年销售额将比预期更大幅度下滑，原因是定价压力对其在美国市场广受欢迎的糖尿病和减肥药的销售造成冲击。
这家丹麦公司表示，剔除汇率波动影响后，预计2026年全球全年销售额将比2025年水平下降5%至13%。相比之下，2025年全年销售额增长了10%。
公司指出，美国销售额预计将因包括Ozempic和Wegovy在内的药物价格下降而减少，这与其最近同特朗普政府达成的降价协议有关。此外，这两种药物的活性成分在美国以外的某些国家将失去专利独占权，这可能为低成本仿制药竞争铺平道路。
这一黯淡的前景是这家曾经风光无限的公司的又一坏消息，该公司曾是减肥药市场的开拓者之一。
（本文结束）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.